echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Pfizer's Mertoviline generic Ruxience, approved by the European Union

    Pfizer's Mertoviline generic Ruxience, approved by the European Union

    • Last Update: 2020-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pfizer has received EU approval for the biosimilar Ruxience (rituximab) biosimilar to CD20 monomera (rituxira, mabThera, rituximab)approved for the use of Ruxience for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granuloma with polyvascularitis (GPA) and micropolyvasitis (MPA) and common herpes (PV)the decision was based on a series of data on the biological similarity of Ruxience and MabThera, including results from a clinical comparative study of REFLECTIONS B3281006, which evaluated Ruxience's efficacy, safety, immunoogenics, pharmacokinetics, and pharmacodynamic parametersThe data showed that Ruxience "had no clinically significant difference sable in CD20-positive, low tumor-loaded follicles patients with the safety or efficacy of MabThera." Masum Hossain, regional president ofPfizer Oncology International Development Market, added: "Biosimilars like Ruxience have similar safety and efficacy to the original product and can significantly reduce healthcare costs"
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.